Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism

29 Apr 2020

• By Joseph Haas

Happy Hopeful Woman Looking at the Sunset by the Sea. Silhouette of a dreamer girl looking hopeful at the horizon — Analysts and NIAID director Fauci called the data significant and reason for optimism

Related Content

Remdesivir Potentially Most Effective For Coronavirus: China Investigator

09 Mar 2020

Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak

24 Apr 2020

Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely

14 Apr 2020

'Peoples' Hope' Remdesivir Results Due Soon - What To Look For?

09 Apr 2020

Coronavirus: Gilead Readies For Remdesivir Ramp Up, Questions On Profit Motive

03 Mar 2020

COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial

17 Mar 2020

Related Companies

Gilead Sciences, Inc.

Roche Holding AG

Additional Topics

Coronavirus COVID-19 Clinical Trials Drug Approval Standards Research & Development Infectious Diseases BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.